Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 14;11:535147. doi: 10.3389/fimmu.2020.535147

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Santaterra, Fiusa, Hounkpe, Chenou, Tonasse, da Costa, Garcia-Weber, Domingos, Lima, Borba-Junior, Araújo, Lucena-Araújo, Bezerra, dos Santos, Costa, Millán and De Paula

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Heme-induced EB disruption in the presence of serum is associated with hemopexin levels. (A) Hemopexin levels were measured by Elisa and were lower in SCD patients (n=19) compared to healthy volunteers (n=10) (Mann-Whitney test). (B) A strong negative correlation was observed between hemopexin and heme levels (Spearman correlation coefficient). (C) Lower values of normalized resistance at the timepoint of peak heme-induced EB disruption were observed in individuals with lower hemopexin levels (t test). Accordingly, peak heme-induced EB disruption (i.e., after 12 min) was statistically correlated with hemopexin levels (Spearman correlation coefficient) (D).